Elig.phs000862.v1.p1.1
Item
Samples were taken from participants in the following four studies:
boolean
C0200345 (UMLS CUI [1,1])
Elig.phs000862.v1.p1.2
Item
MIRC-001 (NCT 00215527, P. Dickson, PI): This is a pilot, 4-month study of 1.75 mg IT laronidase (recombinant human alpha-L-iduronidase) given monthly via lumbar spinal tap to MPS I patients age 8 years and older with spinal cord compression.
boolean
C0087111 (UMLS CUI [1,1])
C1302054 (UMLS CUI [1,2])
C0023786 (UMLS CUI [1,3])
C0001779 (UMLS CUI [1,4])
C0037926 (UMLS CUI [1,5])
Elig.phs000862.v1.p1.3
Item
MIRC-001 (100) (NCT 00786968, P. Dickson, PI): This is an extension study for MIRC-001. Subjects with good response to IT laronidase defined by improvement in any outcome measure and no safety concerns receive 12 months of additional therapy at 30 to 90 day intervals.
boolean
C0205170 (UMLS CUI [1,1])
C0521982 (UMLS CUI [1,2])
C1302054 (UMLS CUI [1,3])
C1706712 (UMLS CUI [1,4])
Elig.phs000862.v1.p1.4
Item
MIRC-002 (NCT 00852358, P. Dickson, PI): This is a 1-year randomized controlled study followed by 1-year open label phase of 1.75 mg IT laronidase given at 30 to 90 day intervals to MPS I patients age 6 years and older with cognitive impairment or decline.
boolean
C0087111 (UMLS CUI [1,1])
C1302054 (UMLS CUI [1,2])
C0023786 (UMLS CUI [1,3])
C0001779 (UMLS CUI [1,4])
C0338656 (UMLS CUI [1,5])
Elig.phs000862.v1.p1.5
Item
MT2007 (NCT 00638547, P. Orchard, PI): This is a 1-year study of 0.05 mg/kg IT laronidase given at 90 day intervals to MPS I Hurler patients age 0.5-3 years in conjunction with weekly 0.58 mg/kg IV laronidase and hematopoietic stem cell transplantation.
boolean
C0087111 (UMLS CUI [1,1])
C1302054 (UMLS CUI [1,2])
C0472699 (UMLS CUI [1,3])
C0023786 (UMLS CUI [1,4])
C0001779 (UMLS CUI [1,5])